• Explore /
  • Poster
  • / A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.

A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.

Abstract Poster

Authors

null

Esther W. Bouman-Wammes

VU University Medical Center, Amsterdam, Netherlands

Esther W. Bouman-Wammes , Linda de Munck , H Pieter van den Berg , Aart Beeker , Carolien H. Smorenburg , Henk M.W. Verheul , Winald R. Gerritsen , Alfonsus Johannes Maria van den Eertwegh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NTR3070

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 166)

DOI

10.1200/JCO.2017.35.6_suppl.166

Abstract #

166

Poster Bd #

F20

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).

Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).

First Author: Lara Pemberton

First Author: C. W. Reuter

First Author: Thiago Bueno Oliveira Sr.

First Author: Padmanee Sharma